June 21, 2022
1 min watch
Akinboro O, et al. Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50 %: FDA pooled analysis. Presented at: ASCO Annual meeting; June 3-7, 2022; Chicago.
Nakajima EC, et al. Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. Presented at: ASCO Annual meeting; June 3-7, 2022; Chicago.
In this video, Melina MarmarelisMD, discussed results from two FDA pooled analyses in lung cancer that were presented at the ASCO annual meeting.
“We need better indicators for what is high-risk disease in order to choose patients who could benefit from chemotherapy because clearly there’s a population that can really benefit from chemotherapy, even in the high PD-L1 group,” Marmarelis, assistant professor of medicine at the University of Pennsylvania, said.